Iron deficiency anemia can be rapidly corrected and managed with intravenous iron products; however, rare hypersensitivity or anaphylactic reactions associated with their administration have occurred.

Reporting rates of hypersensitivity and anaphylactic reactions with four intravenous iron preparations (iron dextran, iron sucrose, ferumoxytol, and ferric carboxymaltose) were assessed based on the US Food and Drug Administration Adverse Event Reporting System database.

There were differential reporting rates of hypersensitivity and anaphylactic reactions for intravenous iron products, with ferric carboxymaltose exhibiting the lowest reporting rate and the lowest downstream medical costs per adverse event.